Drug Discovery@nature.com 17 January 2014

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS 17 January 2014 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement nature.com webcasts Macmillan Science Communication presents a custom webcast series: Drugging the Human Methylome   Two independent, but complimentary, webcasts and live Q & A's broadcasting on:   21 January    23 January    Sponsored by: Epizyme    News Top FDA approvals usher in the post-interferon era in HCV doi:10.1038/nbt0114-3 Recent FDA approvals of the oral HCV drugs sofosbuvir and simeprevir could change the landscape of HCV treatment through improved efficacy and by enabling patients to avoid complicated treatment regimens and adverse effects of interferon therapy. Full Text Genentech's glyco-engineered antibody to succeed Rituxan doi:10.1038/nbt0114-6b Obinutuzumab, a glyco-engineered antibody developed as a successor to the blockbuster rituximab, has received FDA approval for chronic lymphocytic leukaemia. It is the first such antibody to reach Western markets, and the first candidate to gain approval under the FDA's breakthrough therapy pathway. Full Text Juno's whopping $120 million success signals new investing style doi:10.1038/nm0114-4 Juno Therapeutics has secured $120 million in its first-round bid for venture capital to support the development of cancer drugs using an innovative immunotherapy platform — the largest such early financing deal in biotech history. Full Text Companion therapeutics doi:10.1038/nbt.2793 Gunjan Sinha reports on how a growing market for therapeutic drugs for pets is fostering a startup boom. Full Text Analysis Top Light it up doi:10.1038/scibx.2014.1 A team has designed fluorescent nanoparticles that can light up tumours regardless of genotype or phenotype, potentially allowing surgeons to achieve more complete tumour resection. Full Text UK academic drug discovery doi:10.1038/nrd4200 This article presents a survey of the academic drug discovery environment in the United Kingdom in 2013, and discusses the major trends in comparison with the United States. Full Text Research Highlights Top Viral diseases: Zeroing in on RSV vaccine design doi:10.1038/nrd4207 Structure-based design produces a novel vaccine for respiratory syncytial virus, which shows a high level of neutralizing activity in mice and rhesus macaques. Full Text Antibacterial drugs: Persisters come under fire doi:10.1038/nrd4215 Two studies report novel approaches to eradicate bacterial persisters, which complicate the treatment of chronic infections as they are recalcitrant to killing by antibiotics. Full Text A step closer to elimination? doi:10.1038/nrd4216 A group of scientists from academia and industry report the discovery of a new class of antimalarials with promising preventive, therapeutic and transmission-blocking activity. Full Text Research & Reviews Top Therapeutic targeting of EPH receptors and their ligands doi:10.1038/nrd4175 EPH receptor (EPH)–ephrin signalling has crucial roles in embryonic development, as well as in adult tissue and organ maintenance, regeneration and pathogenesis. This article discusses the potential and limitations of targeting EPH–ephrin function in the treatment of disorders including cancer, neurological diseases and inflammation. Full Text The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment doi:10.1038/nrd4161 The Hippo signalling pathway is an emerging growth control pathway with roles in organ growth control, stem cell function, regeneration and tumour suppression. This article reviews the regulation and functions of the Hippo signalling pathway, focusing on its potential to be therapeutically targeted in the treatment of cancer as well as tissue repair and regeneration following injury. Full Text Tetraspanin proteins promote multiple cancer stages doi:10.1038/nrc3640 This Review discusses recent evidence, particularly from mouse models, showing that some tetraspanin proteins have important roles in tumour initiation, promotion, metastasis and angiogenesis, and that they might therefore be valid therapeutic targets. Full Text Ribosome-targeting antibiotics and mechanisms of bacterial resistance doi:10.1038/nrmicro3155 The ribosome is one of the primary antibiotic targets in the bacterial cell. This review discusses how high-resolution crystal structures of antibiotic–ribosome complexes have provided molecular insight into the mechanisms of antibiotic action and bacterial resistance, in addition to the approaches being pursued for the development of improved and novel ribosome-targeting antibiotics. Full Text Drug Discovery JOBS of the week Development of novel treatment for drug-resistant leukemia Oslo University Hospital PhD in Cancer Research / Pharmacology University of Marburg, Inst. of Pharmacology Assistant Professor - Department of Pharmacology, Université de Sherbrooke, Québec, Canada Université de Sherbrooke Post-Doctoral Bioinformatician University of Dundee Postdoctoral Scientist – Medicinal Chemistry Infectious Disease Research Institute (IDRI) More Science jobs from Drug Discovery EVENT Anti-Obesity Drug Discovery and Development 03.04.14 London, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.